SLC7A11 and ovarian carcinoma: On this basis, PARPi combined with FINS targeting SLC7A11 or GPX4 can synergistically enhance ferroptosis, thereby producing an effective tumor suppression effect against BRCA (wild type) ovarian cancer (50).Similarly, Apatinib combined with olaparib reduced GPX4 by inhibiting expression of NRF2 and autophagy, inducing ferroptosis in ovarian cancer.